Revanesse Versa, Revanesse Versa+ (with lidocaine) and Revanesse Lips+ (with lidocaine)
Prollenium Medical Technologies, Inc. · Decision date Oct 14, 2026
What did the FDA decide?
The FDA record for P160042/S032 describes a 30-day notice submitted by Prollenium Medical Technologies, Inc. Its stated purpose is approval to qualify a third-party logistics (3PL) supplier for warehousing and temperature-controlled storage of Revanesse Versa, Revanesse Versa+, and Revanesse Lips+ finished products. The supplement reason is listed as a process change covering manufacturer, sterilizer, packager or supplier.
The S032 identifier places this as a supplement to PMA P160042; it is not a new approval of the whole device system, and the notice concerns a supplier and storage arrangement rather than a clinical claim. The record does not identify the 3PL supplier, the storage site, temperature ranges, or any safety or effectiveness data, so the reported purpose should be read as the applicant's stated scope, not as independent evidence of product performance.
The device category is an implant, dermal, for aesthetic use, with product code LMH.
FDA approval order statement
Approval to qualify a Third-Party Logistics (3PL) supplier for warehousing and temperature-controlled storage of Revanesse Versa, Revanesse Versa+, and Revanesse Lips+ finished products
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Oct 14, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160042/S032
- Regulatory pathway
- PMA supplement
- Product code
- LMH
- Decision code
- OK30
- Decision date
- Oct 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Product code
- LMH
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P160042. Subsequent supplements may change the device or its indications.
FDA decision timeline
P160042 · Original PMA
REVANESSE ULTRA
P160042/S032 received
Application receipt date recorded by FDA.
P160042/S032 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P160042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
REVANESSE ULTRAP160042 | Prollenium Medical Technologies, Inc. | PMA approval | Aug 4, 2017 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Prollenium Medical Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 138 Industrial Pkwy. N., Aurora, L4G 4C3
Sources and methodology
- Original FDA record: P160042/S032
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


